|Systematic (IUPAC) name|
|(what is this?)|
Loracarbef is an antibiotic. It is a carbacephem, but it is sometimes grouped together with the second-generation cephalosporin antibiotics. Loracarbef is a synthetic "carba" analog of cefaclor, and is more stable chemically.
Loracarbef received FDA approval in 1991 and it was marketed under the trade name Lorabid. Its use was discontinued in 2006.
Diarrhea is the most common adverse effect with loracarbef. Side effects are more frequently seen with children under the age of twelve.
- Biedenbach DJ, Jones RN (February 1994). "Predictive accuracy of disk diffusion test for Proteus vulgaris and Providencia species against five newer orally administered cephalosporins, cefdinir, cefetamet, cefprozil, cefuroxime, and loracarbef". J. Clin. Microbiol. 32 (2): 559–62. PMC 263078. PMID 8150976.
|This systemic antibacterial-related article is a stub. You can help Wikipedia by expanding it.|